Sarah C. Mutka

1.0k total citations
22 papers, 819 citations indexed

About

Sarah C. Mutka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Sarah C. Mutka has authored 22 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Physiology. Recurrent topics in Sarah C. Mutka's work include Advanced Breast Cancer Therapies (7 papers), Nitric Oxide and Endothelin Effects (6 papers) and Eicosanoids and Hypertension Pharmacology (5 papers). Sarah C. Mutka is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Nitric Oxide and Endothelin Effects (6 papers) and Eicosanoids and Hypertension Pharmacology (5 papers). Sarah C. Mutka collaborates with scholars based in United States, Spain and Italy. Sarah C. Mutka's co-authors include John R. Carney, Peter Walter, Yaoquan Liu, Jonathan Kennedy, Steven D. Dong, Wenqing Yang, Sumati Murli, Pieter B.M.W.M. Timmermans, Shannon L. Ward and Gary J. Rosenthal and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Sarah C. Mutka

20 papers receiving 789 citations

Peers

Countries citing papers authored by Sarah C. Mutka

Since Specialization

Citations

This map shows the geographic impact of Sarah C. Mutka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah C. Mutka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah C. Mutka more than expected).

Fields of papers citing papers by Sarah C. Mutka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah C. Mutka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah C. Mutka. The network helps show where Sarah C. Mutka may publish in the future.

Co-authorship network of co-authors of Sarah C. Mutka

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah C. Mutka. A scholar is included among the top collaborators of Sarah C. Mutka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah C. Mutka. Sarah C. Mutka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1 2025 ·Annals of Oncology ·(unknown), (unknown), G. Curigliano, (unknown), Massimo Cristofanilli, S-B. Kim, (unknown), Jorge Nadal, (unknown), George Emile, Robert Wesolowski, Miguel Martín, (unknown), Sarah C. Mutka, Sayaka Suzuki, (unknown), Igor Gorbatchevsky, (unknown)	1
2	Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer 2025 ·Clinical Cancer Research ·Robert Wesolowski, Hope S. Rugo, Jennifer M. Specht, Hyo S. Han, Peter Kabos, Ulka N. Vaishampayan, Seth A. Wander, Keerthi Gogineni, Alexander I. Spira, Anne F. Schott, Maysa Abu‐Khalaf, Sarah C. Mutka, Samuel Suzuki, (unknown), Igor Gorbatchevsky, Rachel M. Layman	0
3	Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study 2024 ·The Lancet Oncology ·Rachel M. Layman, Hyo S. Han, Hope S. Rugo, Erica Stringer-Reasor, Jennifer M. Specht, Elizabeth Claire Dees, Peter Kabos, Samuel Suzuki, Sarah C. Mutka, (unknown), Igor Gorbatchevsky, Robert Wesolowski	31
4	204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients 2023 ·ESMO Open ·Hope S. Rugo, Robert Wesolowski, Erica Stringer-Reasor, Hyo S. Han, Jennifer M. Specht, (unknown), Peter Kabos, Ulka N. Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander I. Spira, Anne F. Schott, Maysa Abu‐Khalaf, Sarah C. Mutka, Samuel Suzuki, Igor Gorbatchevsky, Rachel M. Layman	1
5	Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) 2023 ·Cancer Research ·Sara A. Hurvitz, Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, (unknown), Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope S. Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl	2
6	A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer 2022 ·British Journal of Cancer ·Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, María Alsina, (unknown), Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark R. Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nazima Pathan, (unknown), Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg	24
7	Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors 2021 ·Cancer Research ·Salmaan Khan, (unknown), (unknown), Ian A. MacNeil, (unknown), Sarah C. Mutka, (unknown), (unknown), Laura Milligan, (unknown), (unknown), Lance Laing	2
8	Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation 2014 ·BMC Pulmonary Medicine ·(unknown), Sarah C. Mutka, Xicheng Sun, Jian Qiu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jane P. Richards, (unknown), Charles H. Scoggin, Gary J. Rosenthal	42
9	Pharmacological inhibition ofS-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo 2013 ·Journal of Applied Physiology ·Qiumei Chen, Richard E. Sievers, Mónika Varga, Sourabh Kharait, Daniel Haddad, (unknown), (unknown), Sarah C. Mutka, (unknown), Gregory P. Dubé, Gary J. Rosenthal, Matthew L. Springer	39
10	Structure–activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: Carboxamide modification 2012 ·Bioorganic & Medicinal Chemistry Letters ·Xicheng Sun, Jian Qiu, (unknown), Louis S. Green, Jan W. F. Wasley, (unknown), Dorothy B. Colagiovanni, (unknown), Sarah C. Mutka, Jane P. Richards, Gary J. Rosenthal	12
11	ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer 2012 ·PLoS ONE ·Sarah C. Mutka, (unknown), Evie L. Verderber, Jane P. Richards, (unknown), Elizabeth A. Chlipala, Gary J. Rosenthal	9
12	Structure–activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: Pyrrole regioisomers and propionic acid replacement 2011 ·Bioorganic & Medicinal Chemistry Letters ·Xicheng Sun, Jian Qiu, (unknown), Louis S. Green, Jan W. F. Wasley, Dorothy B. Colagiovanni, Sarah C. Mutka, (unknown), (unknown), Jane P. Richards, Lawrence Chun, Gary J. Rosenthal	15
13	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities 2011 ·Bioorganic & Medicinal Chemistry Letters ·Xicheng Sun, Jian Qiu, (unknown), Louis S. Green, Jan W. F. Wasley, (unknown), Dorothy B. Colagiovanni, Sarah C. Mutka, (unknown), Jane P. Richards, Gary J. Rosenthal	22
14	Discovery of S-Nitrosoglutathione Reductase Inhibitors: Potential Agents for the Treatment of Asthma and Other Inflammatory Diseases 2011 ·ACS Medicinal Chemistry Letters ·Xicheng Sun, Jan W. F. Wasley, Jian Qiu, (unknown), (unknown), Louis S. Green, (unknown), Dorothy B. Colagiovanni, Jane P. Richards, Sarah C. Mutka, Lawrence Chun, Gary J. Rosenthal	46
15	Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation And Decrease Airspace Enlargement In Experimental Models Of Chronic Obstructive Pulmonary Disease 2011 ·(unknown), Sarah C. Mutka, (unknown), Bassam B. Damaj, (unknown), (unknown), Xicheng Sun, Gary J. Rosenthal, Charles H. Scoggin	3
16	Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo 2009 ·Cancer Research ·Sarah C. Mutka, Wenqing Yang, Steven D. Dong, Shannon L. Ward, (unknown), Pieter B.M.W.M. Timmermans, Sumati Murli	166
17	Metabolic pathway engineering for complex polyketide biosynthesis inSaccharomyces cerevisiae 2006 ·FEMS Yeast Research ·Sarah C. Mutka, (unknown), John R. Carney, Nancy A. Da Silva, James T. Kealey	61
18	Heterologous Production of Epothilone C and D in Escherichia coli 2006 ·Biochemistry ·Sarah C. Mutka, John R. Carney, Yaoquan Liu, Jonathan Kennedy	116
19	Multifaceted Physiological Response Allows Yeast to Adapt to the Loss of the Signal Recognition Particle-dependent Protein-targeting Pathway 2001 ·Molecular Biology of the Cell ·Sarah C. Mutka, Peter Walter	75
20	Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones. 1992 ·Journal of Biological Chemistry ·Shinichi Hirose, Robert P. Mohney, Sarah C. Mutka, L Ravi, David R. Singleton, George Perry, Alan M. Tartakoff, M. Edward Medof	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact